Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Single-Arm, Multi-Center Study Evaluating the Combination of Vinorelbine and Lapatinib in Women With ErbB2 Overexpressing Metastatic Breast Cancer

NCT00709618 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00709618
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00709618 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Single-Arm, Multi-Center Study Evaluating the Combination of Vinorelbine and Lapatinib in Women With ErbB2 Overexpressing Metastatic Breast Cancer
Lead sponsor
GlaxoSmithKline
Phase
Phase 2
Overall status
Terminated
Start date
June 30, 2008
Completion date
May 31, 2012
Enrollment
44 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasms, breast